Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 7/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490365 | 1.00 | ESR2 (0.46) | ESR2RORCTACR1GPR119USP30 | |
| SCHEMBL9901785 | 0.85 | GPR119 (0.44) | RORCTACR1GPR119USP30PDK2 | |
| SCHEMBL15212259 | 0.85 | RORC (0.48) | RORCTACR1GPR119USP30TSHR | |
| SCHEMBL31125398 | 0.85 | STS (0.47) | ESR2RORCGPR119USP30 | |
| SCHEMBL21826203 | 0.85 | STS (0.47) | ESR2RORCGPR119USP30 | |
| SCHEMBL1309072 | 0.84 | RORC (0.51) | RORCTACR1GPR119TSHRALOX15 | |
| SCHEMBL31084094 | 0.84 | ALDH1A1 (0.52) | RORC | |
| SCHEMBL15689795 | 0.83 | TACR1 (0.47) | RORCTACR1TSHR | |
| SCHEMBL29968258 | 0.83 | RORC (0.39) | ESR2RORCTACR1GPR119USP30 | |
| SCHEMBL28871282 | 0.83 | RORC (0.39) | ESR2RORCTACR1GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | GENENTECH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| CN-110650959-B | Therapeutic compounds and compositions and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220106322-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| CN-114008050-A | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | 豪夫迈·罗氏有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20200352951-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200352951-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| CN-110650959-A | Therapeutic compounds and compositions and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-20190240227-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10307426-B2 | Therapeutic compounds and compositions, and methods of use thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10307426-B2 | Therapeutic compounds and compositions, and methods of use thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180333416-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106322-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | JAK2, JAK1, JAK3 | ESR2 2790/4885RORC 186/4885TACR1 4750/4885 |
| US-20180333416-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | ESR2 4195/4885RORC 140/4885TACR1 4415/4885 |
| US-20190240227-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | ESR2 3644/4885RORC 92/4885TACR1 4060/4885 |
| US-20200352951-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | ESR2 3897/4885RORC 163/4885TACR1 4351/4885 |
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | JAK1, JAK2, CNKSR1 | ESR2 1059/4885RORC 37/4885TACR1 1535/4885 |
| US-10307426-B2 | Therapeutic compounds and compositions, and methods of use thereof | JAK2, JAK1, JAK3 | ESR2 4195/4885RORC 140/4885TACR1 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.